- Home
- SLG vs PCVX Comparison
SLG vs PCVX Comparison
Compare SLG & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLG
- PCVX
- Stock Information
- Founded
- SLG 1980
- PCVX 2013
- Country
- SLG United States
- PCVX United States
- Employees
- SLG N/A
- PCVX N/A
- Industry
- SLG Real Estate Investment Trusts
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- SLG Real Estate
- PCVX Health Care
- Exchange
- SLG Nasdaq
- PCVX Nasdaq
- Market Cap
- SLG 4.6B
- PCVX 4.4B
- IPO Year
- SLG 1997
- PCVX 2020
- Fundamental
- Price
- SLG $62.40
- PCVX $35.63
- Analyst Decision
- SLG Hold
- PCVX Strong Buy
- Analyst Count
- SLG 16
- PCVX 10
- Target Price
- SLG $66.50
- PCVX $136.50
- AVG Volume (30 Days)
- SLG 1.1M
- PCVX 1.5M
- Earning Date
- SLG 07-16-2025
- PCVX 08-05-2025
- Dividend Yield
- SLG 4.93%
- PCVX N/A
- EPS Growth
- SLG N/A
- PCVX N/A
- EPS
- SLG N/A
- PCVX N/A
- Revenue
- SLG $648,551,000.00
- PCVX N/A
- Revenue This Year
- SLG N/A
- PCVX N/A
- Revenue Next Year
- SLG $2.45
- PCVX N/A
- P/E Ratio
- SLG N/A
- PCVX N/A
- Revenue Growth
- SLG N/A
- PCVX N/A
- 52 Week Low
- SLG $45.15
- PCVX $27.66
- 52 Week High
- SLG $82.81
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- SLG 53.75
- PCVX 53.91
- Support Level
- SLG $60.48
- PCVX $31.79
- Resistance Level
- SLG $63.75
- PCVX $34.63
- Average True Range (ATR)
- SLG 1.79
- PCVX 1.38
- MACD
- SLG -0.33
- PCVX 0.09
- Stochastic Oscillator
- SLG 60.14
- PCVX 86.31
About SLG SL Green Realty Corp
SL Green Realty is one of the largest Manhattan property owners and landlords, with interest in around 32 million square feet of wholly owned and joint-venture office space. The company has additional property exposure through its limited portfolio of well-located retail space. It operates as a real estate investment trust.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.